Building the life science of tomorrow: AI, innovation, and the new agency model

CONTEXT: AI and advanced technologies enable life sciences companies to balance cost management with value delivery by accelerating and improving decision-making throughout the drug development life cycle. This means more efficient operations and outcomes, but requires a transformational shift in the industry's traditional practices. Key steps include upskilling clinical and commercial staff and defining desired outcomes before choosing the technology and strategies that will support them.

ISSUE: Rising drug development expenses, limited resources, and economic instability have created a critical need for the life sciences sector to manage costs more effectively. As stakeholders increasingly look toward how artificial intelligence (AI) and other advanced technologies will enhance efficiencies, there is a growing focus on how these innovations enable better outcomes and drive savings.

While the potential benefits are easy to identify, the real challenge lies in the execution. Companies must break away from the status quo to fully leverage these tools at scale and realize their true value.

SOLUTION: Change is inevitable, but we must ensure manufacturers and agencies are prepared for the adoption of AI and advanced technologies. Personnel education and development, coupled with shifts in how organizations have historically operated, are essential for achieving organizational readiness. Long-term success and medical advances can only be realized when processes, teams, and technology are in harmony.

Part 2.